CPT-11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver

Mikiko Shimizu,1, 2 Tomohide Tamura,2 Yasuhide Yamada,2 Yoshiko Akiyama,1, 2 Nagahiro Saijo2 and Kazuto Nishio1, 3

1Pharmacology Division, National Cancer Center Research Institute and 2Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045

Combination chemotherapy consisting of 5-fluorouracil (5-FU) and 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxycamptothecin (CPT-11) is a promising regimen for gastrointestinal cancer. The circadian-dependent efficacy and toxicity of 5-FU are related to the circadian variation in the activity of dihydropyrimidine dehydrogenase (DPD), which is a rate-limiting enzyme in the pyrimidine catabolic pathway. To optimize the schedule of the CPT-11 plus 5-FU combination, we investigated the effect of CPT-11 on the circadian rhythm of DPD in vivo. In control mice, the DPD mRNA level in the liver was significantly higher at 14:00 than that at 02:00. After intravenous administration of CPT-11 (30 mg/kg) at 20:00, the circadian rhythm of the DPD mRNA level in the liver was no longer observed 18 h later (14:00), but it was unaffected 6 and 18 h later (at 14:00 and 02:00) when CPT-11 was given at 08:00. In addition, a dose-dependent lengthening of the period of the circadian rhythm of DPD was observed for 42 h after intravenous injection of CPT-11 at 20:00. The levels of DPD protein and activity at 21 h after administration of CPT-11 (at 17:00) were significantly higher than at 9 h (at 05:00). These results suggest that CPT-11 may influence the circadian rhythm of DPD at the transcriptional level. Modulation of the circadian rhythm of DPD by CPT-11 may be a factor in optimizing the combination of 5-FU and CPT-11.

Key words: CPT-11 — Dihydropyrimidine dehydrogenase — Circadian rhythm

7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carboxycamptothecin (CPT-11) is one of the most potent therapeutic agents for the treatment of solid tumors, including lung, colorectal, and cervical cancer, and malignant lymphoma,1, 2 and combination regimens of CPT-11 and 5-fluorouracil (5-FU) have recently been evaluated in metastatic colorectal cancer patients.3, 4 Combination chemotherapy consisting of CPT-11, 5-FU, and leucovorin has been reported to be well tolerated and to have greater efficacy than 5-FU alone for first-line metastatic colorectal cancer.5

Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in 5-FU catabolism, and it has been found to exhibit circadian variation in experimental animals and cancer patients.8 A study in cancer patients treated with 5-FU showed an inverse relationship between DPD activity in peripheral blood mononuclear cells and the plasma concentration of 5-FU,8 and the circadian variation in 5-FU toxicity in rats has been reported to be inversely correlated with the circadian variation in DPD activity.8 The relevance of chronotherapy using 5-FU, folinic acid, and oxaliplatin was investigated in phase II trials in metastatic colorectal cancer patients.9

The mechanisms regulating circadian rhythms in a variety of species have recently been clarified. In mammals, the suprachiasmatic nucleus (SCN) of the anterior hypothalamus has been shown to be a circadian pacemaker,11 and the human and mouse homologues of the mammalian period gene, which plays a central role in circadian rhythms, have been isolated.12, 13 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) inhibits the synthesis of heterogeneous nuclear RNA and mRNA at the transcription initiation level by interfering with RNA polymerase II function.14, 15 DRB was found to shift the phase and lengthen the period of the circadian rhythm of isolated eyes of Aplysia.16 Camptothecin, a transcription inhibitor whose action is mediated by inhibition of DNA topoisomerase I (topo I), has been observed to have similar effects on circadian rhythms. Based on the findings, it can be speculated that transcriptional regulation through topo I inhibition might alter the circadian rhythm. We therefore hypothesized that CPT-11, a clinically useful derivative of camptothecin, shifts the circadian rhythm of DPD and affects the efficacy and toxicity in combination therapy of CPT-11 and 5-FU. Accordingly, the purpose of this study was to investigate the effect of CPT-11 on the circadian rhythm of DPD in vivo.

MATERIALS AND METHODS

Materials CPT-11 was obtained from Yakult Co., Ltd. (Tokyo) and dissolved in saline for intravenous injection into mice. Anti-DPD polyclonal antibody was provided by

---

1To whom correspondence should be addressed.
E-mail: knishio@gan2.res.ncc.go.jp
chronopharmacology of DPD

**Animals** C57BL male mice (8 weeks old; 19–22 g) were obtained from Charles River Japan Inc. (Yokohama) and exposed to a 12-h light/12-h dark cycle (lights on at 08:00 and off at 20:00) for at least 1 week before the day of the experiment.

**Treatment schedule**

**Experiment 1: Influence of CPT-11 administration time on DPD mRNA levels.** Mice (one mouse in each group) were intravenously injected with CPT-11 (30 mg/kg) at 08:00 or 20:00, and control mice were injected with physiological saline. Mice were sacrificed at 6 and 18 h after the injection, and their brain and liver were removed and stored at −80°C until used.

**Experiment 2: Dose-dependent effects of CPT-11 on hepatic levels of DPD mRNA.** Mice (one mouse in each group) in 4 groups were intravenously injected with different doses of CPT-11 (10, 30, 60, and 100 mg/kg) at 20:00, and control mice were injected with physiological saline. The liver of some of the animals was quickly removed at 6, 18, 30, or 42 h after the injection.

**Experiment 3: Influence of CPT-11 on DPD activity and protein levels.** Mice in separate groups were intravenously injected with one of two doses of CPT-11, 30 or 60 mg/kg, at 20:00, and control mice were injected with physiological saline. Mice (3 mice in each group) were sacrificed at 9 h (at 05:00) or 21 h (at 17:00) after the injection, and liver tissue was collected and stored.

**Northern blot analysis** Total RNA was isolated from liver tissue with Isogen (a guanidine HCl/phenol procedure; Nippon Gene, Tokyo). Total RNA (20 µg) was denatured with formaldehyde, electrophoresed through 1% agarose formaldehyde gel, transferred to a nylon membrane (Hybond-N+, Amersham, Buckinghamshire, UK), and immobilized by UV cross-linking. The DPD cDNA probe was labeled with [α-32P]dCTP (3000 Ci/mmol, 10 mCi/ml, Daiichi Pure Chemicals, Tokyo) by using a random prime labeling system (Rediprime, Amersham) and purified with a Chroma Spin-10 column (Clontech, Palo Alto, CA). The membrane was prehybridized for 2 h at 42°C in hybridization solution [50% (v/v) formamide, 0.65 M NaCl, 0.1 M sodium-pipes (pH 6.8), 5× Denhardt’s solution, 0.1% sodium dodecyl sulfate (SDS), 5 mM ethylenediamine-N,N,N′,N′-tetraacetic acid, disodium salt, dihydrate (EDTA), 100 µg/ml salmon sperm DNA], and hybridized overnight with the probe at 42°C. The membrane was then washed with 2× saline-sodium citrate solution (SSC) and 0.1% SDS for 10 min at 42°C, with 1× SSC and 0.1% SDS for 20 min at 65°C, followed by washing with 0.1× SSC and 0.1% SDS for 20 min at 65°C under the same conditions. The GAPDH cDNA probe was hybridized as described above and used as an internal control for RNA integrity and normalization of RNA loading.

**Preparation of liver cytosol** The liver was washed with ice-cold saline, weighed, minced, and homogenized in 3 volumes of homogenization buffer [35 mM potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose, 1 mM EDTA, 1 mM mercaptoethanol and protease inhibitor (Complete, Boehringer Mannheim GmbH, Mannheim, Germany)]. Each homogenate was centrifuged at 600g for 10 min at 4°C, and the supernatant was centrifuged at 8000g for 10 min at 4°C. This supernatant was centrifuged at 105 000g for 1 h at 4°C, and the cytosol fraction (supernatant) was collected as the enzyme source. The protein concentration was determined with BCA Protein Assay Reagent (PIERCE, Rockford, IL).

**Western blot analysis** Cytosol samples (75 µg each) were mixed with sample buffer (pH 6.8, 80 mM Tris-HCl, 0.1 M dithiothreitol, 15% glycerol, 2% SDS, and 0.6% bromophenol/ethanol) in a final volume of 10 μl, and heated for 5 min at 95°C. Proteins were separated on 7.5% SDS-polyacrylamide gel and transferred onto an Immobilon polyvinylidene difluoride transfer membrane (Millipore, Bedford, MA). The blot was blocked by 5% bovine serum albumin in phosphate-buffered saline (PBS) containing 0.05% Tween-20 overnight at 4°C. The membrane was incubated with rabbit anti-DPD polyclonal antibody (1:1000 dilution) in PBS containing 0.1% Tween-20 (PBST) for 1 h at room temperature, and washed four times with PBST. Next, the DPD bands on the membrane were visualized with biotinylated anti-rabbit IgG (Vector Laboratories, Peterborough, UK) followed by avidin/biotin-horseradish peroxidase ABC kit (Vector Laboratories, Burlingame, CA) and POD immunostaining kit (Wako Pure Chemical Co., Osaka). The DPD proteins on the membrane were quantified densitometrically with a scanner and Photoshop 5.0.

**Immunohistochemical staining for DPD** The paraffin sections of liver were dried, deparaffinized, and incubated in 3% hydrogen peroxide and methanol to inhibit endogenous peroxidase activity. Nonspecific binding sites were blocked with PBS, 3% bovine serum albumin (BSA), and 10% fetal bovine serum (FBS) for 1.5 h. The sections were then incubated with rabbit anti-DPD polyclonal antibody diluted with blocking buffer (1:250 dilution) for 1 h, and after having been washed with PBS, they were treated with biotinylated secondary goat anti-rabbit IgG (1:200 dilution; Vector Laboratories) for 30 min. The sections were then incubated with the ABC kit for 30 min, and DPD was visualized with 3,3-diaminobenzidine (0.05%) as the substrate. The sections were counterstained with veronal acetate-buffered 1% methyl green solution (pH 5.55).
Liver tissue staining was graded as 1+ (weak), 2+ (moderate), or 3+ (strong). Negative control slides incubated without primary antibodies did not show any specific signal.

**Determination of DPD activity in the liver cytosol** DPD activity was estimated on the basis of the rate of production of 5,6-dihydrothymine from thymine in liver cytosol. Linear relationships between the rates of formation of 5,6-dihydrothymine from thymine in liver cytosol.

**Effect of CPT-11 administration time on the hepatic level of DPD mRNA** One of four doses of CPT-11 (10, 30, 60, and 100 mg/kg) was administered to mice in different groups at 20:00, and the DPD mRNA levels in the liver was measured by northern blot analysis 6 and 18 h after injecting mice with CPT-11 at 08:00 or 20:00 (Fig. 1).

In the control mice, the DPD mRNA level in the liver (relative ratio of DPD/GAPDH; 0.65) was markedly higher at 02:00 than that at 14:00 (DPD/GAPDH; 0.41). By contrast, no expression of DPD was detected in the brain at 6 or 18 h after administration of CPT-11 at 08:00 or 20:00. When CPT-11 was administered at 08:00, the DPD mRNA level (DPD/GAPDH) in the liver was 0.50 and 0.27 at 6 and 18 h later (at 14:00 and 02:00), respectively. These variations in DPD levels at 14:00 and 02:00 were similar to those in the controls. When CPT-11 was administered at 20:00, on the other hand, the DPD mRNA level at 14:00 (DPD/GAPDH; 0.35) was almost the same as at 02:00 (DPD/GAPDH; 0.29), suggesting that CPT-11 affects the DPD mRNA level when administered at 20:00.

The diurnal variation of DPD was determined to clarify whether CPT-11 decreased the expression of DPD mRNA or altered the phase and period of the circadian rhythm of DPD. The circadian rhythm of DPD in the control mice exhibited the 24-h cycle determined from the oscillating pattern in Fig. 3, whereas at the 100 mg/kg dose, it extended dose-dependently to a 48-h cycle (Fig. 3).

**RESULTS**

**Effect of CPT-11 administration time on the DPD mRNA level in mouse tissue** To determine whether CPT-11 treatment affects the circadian rhythm of DPD in mice, the DPD mRNA level in liver and brain was examined by northern blot analysis 6 and 18 h after injecting mice with CPT-11 at 08:00 or 20:00 (Fig. 1).
These results suggest that CPT-11 dose-dependently shifts the phase of the circadian rhythm of DPD.

**Effect of CPT-11 on the DPD protein level in liver cytosol** The liver DPD protein level in the CPT-11-treated mice was examined by western blotting. At 6 and 18 h after administration of CPT-11 (at 02:00 and 14:00), no differences in DPD protein level were observed between the three doses of CPT-11 (data not shown). In view of the lag-time in the translation process, the protein levels at 9

![Graph](image)

**Fig. 2.** Dose-dependent effects of CPT-11 on hepatic levels of DPD mRNA after intravenous injection of CPT-11 at 20:00. Mice were intravenously injected with CPT-11 (10, 30, 60, and 100 mg/kg) or saline (control) at 20:00, and the liver was removed at 6 or 18 h later (02:00, 14:00). Total RNA (20 µg/lane) extracted from the liver was subjected to northern blot analysis with a 32P-labeled DPD cDNA probe (first panel) and a GAPDH cDNA probe as a loading and transfer control (second panel). The DPD/GAPDH ratio represents the ratio of the integrated optical densities.

![Graph](image)

**Fig. 3.** Dose-dependent effects of CPT-11 on the circadian rhythm of hepatic levels of DPD mRNA after intravenous injection of CPT-11 at 20:00. Total RNA (20 µg/lane) extracted from liver at various times after administration of CPT-11 (30 mg/kg, ○; 60 mg/kg, △) or saline (control, □) at 20:00 was subjected to northern blot analysis as described in “Materials and Methods.” The relative mRNA level of DPD is expressed as the DPD/GAPDH ratio of integrated optical densities.

![Graph](image)

**Fig. 4.** DPD protein level in liver cytosol after intravenous injection of CPT-11 at 20:00. Cytosol fractions were obtained from the liver as described in “Materials and Methods.” The proteins (75 µg protein/lane) at 9 h (at 05:00; A) or 21 h later (at 17:00; B) were stained with anti-DPD polyclonal antibody by immunoblotting. The arrow indicates 116 kDa. The band corresponding to DPD protein was measured densitometrically after immunoblotting. Each value represents the mean±SD of triplicate determinations. * P<0.05.
and 21 h after administration of CPT-11 (at 5:00 and 17:00) might reflect the mRNA levels at 6 and 18 h (at 02:00 and 14:00), respectively, after administration. The protein level in the liver sample at 05:00 was unaffected by any dose of CPT-11 (Fig. 4A). At 17:00, the DPD protein levels were significantly lower in the CPT-11 treated groups than in the control \((P < 0.05, \text{Fig. 4B})\).

**Immunohistochemistry of DPD expression in mouse liver** To confirm the difference in DPD protein level in the liver between the CPT-11-treated and untreated mice, liver tissue obtained at 6 and 18 h after administration of CPT-11 (at 02:00 and 14:00) was immunohistochemically stained with anti-DPD antibody. 3,3-Diaminobenzidine staining was observed in the cytoplasm of the hepatocytes. No difference in staining was observed in the liver samples obtained at 05:00 after administration of CPT-11 (grade 1, Fig. 5, A, B and C), whereas the cytoplasm of CPT-11-untreated liver cells obtained at 17:00 was stained more diffusely and more deeply for DPD than at 05:00 (grade 3, Fig. 5D). Intensity was weak in the samples obtained from CPT-11-treated mice (60 mg/kg) (grade 1, Fig. 5F). These results were consistent with the results of western blotting.

**Effect of CPT-11 on DPD activity in liver cytosol** To determine whether CPT-11 affects DPD activity, we measured DPD activity in the cytosol fraction of hepatocytes at 9 and 21 h (at 05:00 and 17:00) after intravenous injection of CPT-11 at 20:00. The DPD activity of the samples obtained at 05:00 was similar at all three different doses of CPT-11 \((181.4 \pm 4.8, 163.1 \pm 18.2, \text{and} 180.2 \pm 30.4 \text{pmol/min/mg protein at 0, 30, and 60 mg/kg, respectively, Fig. 6A})\). On the other hand, at 17:00, DPD activity was decreased in the hepatocyte cytosol of mice treated with CPT-11, and the activity of the samples treated with 30 mg/kg \((176.6 \pm 19.6 \text{pmol/min/mg protein})\) and 60 mg/kg \((172.3 \pm 41.4 \text{pmol/min/mg protein})\) was significantly lower than that of the control \((237.4 \pm 34.4 \text{pmol/min/mg protein})\) \((P < 0.05, \text{Fig. 6B})\). These results were consistent with the results of western blotting.

**DISCUSSION**

Many circadian rhythms in physiology and behavior have been described in a wide range of species, from bacteria to humans. Because there are significant circadian rhythms in enzyme activity, renal function, blood
flow,23) and protein binding,24) the pharmacokinetics and pharmacodynamics of many drugs are affected by circadian variations.25, 26) DPD, a major catabolic enzyme of 5-fluorouracil (5-FU), has been reported to exhibit a circadian rhythm, and the variations have been correlated with the efficacy and toxicity of 5-FU in experimental animals6, 7) and cancer patients.8) Zhang et al. have reported that DPD activity in rat liver exhibits a circadian variation, with peak DPD activity at 01:00–02:00 and trough activity at 13:00–14:00, and an approximately 2-fold difference in activity between the maximum and minimum points.9) In our study, the DPD mRNA level in mouse liver at 02:00 was markedly higher than that at 14:00 (Fig. 1), and this finding was consistent with the above-described results. Dose-dependent changes in the period of the circadian rhythm of DPD mRNA levels in mice were observed in response to CPT-11 treatment at 20:00 (Fig. 2). We repeated the northern blotting experiment more than twice, and the same effect of CPT-11 on the circadian rhythm was confirmed by real-time RT-PCR (data not shown). These results suggest that CPT-11 regulates the circadian rhythm of DPD in the transcription level in a manner similar to that of DRB and camptothecin.10) After the present study, the molecular mechanism of action of CPT-11 at the transcription level of DPD remains unclear. Recently, a 1.85 kb 5′ flanking region upstream of the translation start site in exon 1 of the human DPD gene (DPYD gene, GenBank Accession No. AF214571) was cloned.27) Cis-acting elements, including TATA and inverted CCAAT motifs, were identified within this region. This flanking region was able to up-regulate transcription in cultured human pancreatic carcinoma Hs766T cells. The mRNA level of DPD has been found to be higher in the human liver than in the colon,28) and DPD protein level and activity are higher in human liver and PBMCs than in other tissues.29) Putative binding sites for liver-enriched transcription factors have been identified in the 1.85 kb 5′ flanking region of the human DPD gene,27) and tissue-specific DPD expression may therefore be controlled by liver-enriched transcription factors, such as NHF-4 and C/EBP. For all of these reasons, we hypothesize that CPT-11 affects cis-acting elements in the 5′ flanking region of the DPD gene or its trans-acting factors. CPT-11 may also affect the stability of DPD mRNA.

CPT-11 inhibits gene transcription via inhibition of topo I,17) and circadian rhythms of topo I activity and DNA synthesis have been found in mouse bone marrow cells.30) Intraperitoneal injection of CPT-11 when topo I activity and DNA synthesis in mice bone marrow cells begin to increase (in the middle of the night and in the early morning) resulted in higher toxicity in mice, and higher plasma concentrations of CPT-11 and its active metabolite SN-38 have been observed in mice injected with CPT-11 at 05:00 than at 17:00.30) Thus, it is likely that the pharmacokinetics and pharmacodynamics of CPT-11 itself are affected by the circadian rhythm.

Uetake et al. have reported a significant correlation between DPD activity and mRNA expression in the tumor tissue of patients with colorectal cancer, but not in normal mucosa.31) Takenoue et al., on the other hand, have reported that the immunohistochemical score was correlated with DPD protein expression and activity in human mononuclear cells, colorectal cancer cell lines and colorectal cancer specimens, but not with mRNA expression.32) DPD mRNA levels have been reported to be significantly lower in colorectal tumor tissue than in normal tissue, but no difference was observed at the protein or enzyme activity level, suggesting transcriptional and translational regulation of DPD activity.33) In our study, the activity of the samples obtained at 6 and 18 h after CPT-11 administration (at 02:00 and 14:00) did not reflect the DPD mRNA levels at the same times (data not shown). The protein levels and the immunohistochemistry scores at 05:00 and 17:00 appeared to reflect the mRNA levels at 02:00 and 14:00, respectively (Figs. 4–6), suggesting that a lag-time exists in the translation process.

We demonstrated that CPT-11 affects the circadian rhythm of DPD activity, suggesting that the anticancer effect of 5-FU may be affected by circadian modification of DPD by CPT-11. The chronopharmacology of CPT-11 and 5-FU will be helpful in reducing the toxic effects of 5-FU and CPT-11 and in increasing their therapeutic potential. There have been no consistent data on the optimal sequence of CPT-11 and 5-FU in previous studies. It has been reported that CPT-11 before 5-FU was the best sequence and yielded a significant increase in therapeutic

Fig. 6. DPD enzyme activity in liver cytosol after intravenous injection of CPT-11 at 20:00. Cytosol fractions were obtained from the liver at 9 h (at 05:00; A) and 21 h (at 17:00; B) after intravenous injection of CPT-11 (30 and 60 mg/kg) or saline (control) at 20:00. DPD enzyme activity in liver cytosol was determined by HPLC by measuring the rate of production of dihydrothymine from thymine (100 µM). Each value represents the mean±SD of triplicate determinations. * P<0.05.
index over the other schedules tested in rats: CPT-11 simultaneously with 5-FU, and 5-FU 24 h before CPT-11.

On the other hand, discrepant results have been reported between in vivo and in vitro. CPT-11 followed by 5-FU yielded the highest toxicity in mice of the three schedules mentioned above, and higher antitumoral activity was noted when CPT-11 and 5-FU were administered sequentially. Based on our findings, the sequence of 5-FU before CPT-11 might be the best schedule, because the pharmacokinetics and pharmacodynamics of 5-FU would be less affected by CPT-11-induced modification of the circadian rhythm of DPD. We plan to investigate the efficacy of a circadian-based combination schedule of CPT-11 and 5-FU in a colorectal tumor model.

ACKNOWLEDGMENTS

This work was supported in part by Grants-in-Aid for the 2nd Term of the Comprehensive 10-Year Strategy for Cancer Control. The authors wish to thank Dr. Fukushima for providing the anti-DPD polyclonal antibody.

(Received December 8, 2000/Revised February 20, 2001/Accepted February 23, 2001)
18) Ishida, N. Molecular biological approach to the circadian clock mechanism. *Neurosci. Res.*, **23**, 231–240 (1995).

19) Nair, V. and Casper, R. The influence of light on daily rhythm in hepatic drug metabolizing enzymes in rat. *Life Sci.*, **8**, 1291–1298 (1969).

20) North, C., Feuers, R. J., Scheving, L. E., Pauly, J. E., Tsai, T. H. and Casciano, D. A. Circadian organization of thirteen liver and six brain enzymes of the mouse. *Am. J. Anat.*, **162**, 183–199 (1981).

21) Tateishi, T., Fujimura, A., Miura, T. and Ebihara, A. Chronopharmacological study of furosemide in human subjects. *Int. J. Clin. Pharmacol. Res.*, **8**, 401–407 (1988).

22) Koopman, M. G., Krediet, R. T. and Arisz, L. Circadian rhythms and the kidney. A review. *Neth. J. Med.*, **28**, 416–423 (1985).

23) Lemmer, B. and Nold, G. Circadian changes in estimated hepatic blood flow in healthy subjects. *Br. J. Clin. Pharmacol.*, **32**, 627–629 (1991).

24) Vachon, C. and Savoie, L. Circadian variation of food intake and digestive tract contents in the rat. *Physiol. Behav.*, **39**, 629–632 (1987).

25) Reinberg, A. and Smolensky, M. H. Circadian changes of drug disposition in man. *Clin. Pharmacokinet.*, **7**, 401–420 (1982).

26) Levi, F. Cancer chronotherapy. *J. Pharm. Pharmacol.*, **51**, 891–898 (1999).

27) Collie-Duguid, E. S., Johnston, S. J., Powrie, R. H., Milano, G., Etienne, M. C., Rochat, B., Watson, G. C. and McLeod, H. L. Cloning and initial characterization of the human DPYD gene promoter. *Biochem. Biophys. Res. Commun.*, **271**, 28–35 (2000).

28) Johnston, S. J., Ridge, S. A., Cassidy, J. and McLeod, H. L. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. *Clin. Cancer Res.*, **5**, 2566–2570 (1999).

29) Ho, D. H., Townsend, L., Luna, M. A. and Bodey, G. P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. *Anticancer Res.*, **6**, 781–784 (1986).

30) Ohdo, S., Makinosumi, T., Ishizaki, T., Yukawa, E., Higuchi, S., Nakano, S. and Ogawa, N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. *J. Pharmacol. Exp. Ther.*, **283**, 1383–1388 (1997).

31) Uetake, H., Ichikawa, W., Takechi, T., Fukushima, M., Nihei, Z. and Sugihara, K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. *Clin. Cancer Res.*, **5**, 2836–2839 (1999).

32) Takenoue, T., Kitayama, J., Takei, Y., Umetani, N., Matsuda, K., Nita, M. E., Hatano, K., Tsuruo, T. and Nagawa, H. Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. *Ann. Oncol.*, **11**, 273–279 (2000).

33) Johnston, S. J., Ridge, S. A., Cassidy, J. and McLeod, H. L. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. *Clin. Cancer Res.*, **5**, 2566–2570 (1999).

34) Cao, S. and Rustum, Y. M. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. *Cancer Res.*, **60**, 3717–3721 (2000).

35) Guichard, S., Cussac, D., Hennebelle, I., Bugat, R. and Canal, P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. *Int. J. Cancer*, **73**, 729–734 (1997).

36) Guichard, S., Hennebelle, I., Bugat, R. and Canal, P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. *Biochem. Pharmacol.*, **55**, 667–676 (1998).